CharonY Posted June 1, 2018 Posted June 1, 2018 (edited) On 5/31/2018 at 8:39 AM, swansont said: IOW if it's for people who haven't responded to traditional treatments the the disease has likely progressed quite far, so even if the treatment is effective, they may be too far gone to be saved. i.e. it would have helped when they were first diagnosed, but can't save them once they get extremely sick. I don't that kind of data tells you much about the intended use of the drug. That is one of the provisions of the bill, folks that can be part of a trial are not eligible. Also, the data cannot be used in lieu of a full Phase II. The provisions in the bill apparently aim to increase the willingness of manufacturers to provide medication to terminal patients outside of trials (as manufacturers are rather hesitant to provide drugs for above outlined reasons). Most critics argue that it won't do a thing, so. After all, even in states with Right to Try laws they are barely used (in comparison to FDA expanded access requests). But the single biggest issue of course is the political move to diminish the role of the FDA at the cost of affected individuals. Edited June 1, 2018 by CharonY
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now